In clinical trials of systemic therapy for advanced hepatocellular carcinoma (HCC), Asian trials almost always reported poorer survival than non-Asian trials. This study sought to identify contributory factors for this geographic difference. A systematic review was done on randomized trials for unresectable HCC that used systemic therapy as an experimental arm and placebo or supportive care as control. Meta-analysis was performed with the consideration of fixed and random effects. Then, meta-regression was performed to identify predictors of patient survival in the control arm and the treatment effects (improvement in median survival). Fourteen trials (6 Asians, 8 non-Asians) were eligible for meta-analysis. The median survival of patients in the control arm, which indicated natural history of advanced HCC patients, was 3.57+/-1.88 months in Asian trials and 5.96+/-1.46 months in non-Asian trials (p=0.02). Independent predictors of better survival included non-Asian trials (p=0.0007), higher percentage of Child A cirrhosis (p=0.01) and hepatitis B (HBV)-related HCC (p=0.02). Sub-group analysis suggested that Asian trials tended to enroll patients with more advanced diseases. Independent predictors of better treatment effect included non-Asian trials, higher percentage of extra-hepatic metastasis, HBV-related HCC, and poorer trial quality. The quantitative estimation of the geographic difference can help design of future clinical trials of advanced HCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cct.2009.08.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative Efficacy and Safety of Oral Semaglutide in Asians and Non-Asians Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Diabetes Ther
January 2025
First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Department of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical, University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Institute of Nephrology, Jinan, China.
Introduction: More than half of diabetes patients are Asians, and their tolerance to antidiabetic drugs may differ from that of non-Asians. Oral semaglutide has recently gained attention for its advantages in glycemic and body weight control. However, its effects across different ethnic groups remain unknown.
View Article and Find Full Text PDFBackground: In TALAPRO-2, the poly(ADP-ribose) polymerase inhibitor talazoparib plus the androgen receptor-signaling inhibitor enzalutamide improved radiographic progression-free survival (rPFS) versus placebo plus enzalutamide (hazard ratio [HR] = 0.63; 95% CI, 0.51-0.
View Article and Find Full Text PDFInfluence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis.
Breast
November 2024
Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli, Italy. Electronic address:
Article Synopsis
- The study focuses on the effectiveness and safety of combining cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with endocrine therapy (ET) in treating hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer, specifically comparing Asian and non-Asian patients.
- A meta-analysis of 11 studies involving over 5,000 patients was conducted to analyze progression-free survival (PFS) and overall survival (OS) outcomes, as well as treatment-related adverse events.
- Results showed that adding CDK4/6i to ET significantly improved both PFS and OS in both patient groups, indicating the treatment's effectiveness across diverse populations.
Prognostic and predictive factors in advanced upper gastrointestinal cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis of the current evidence.
BMC Cancer
October 2024
Department of Pharmacy, The First Hospital of China Medical University, Shenyang, Liaoning, PR China.
Article Synopsis
- Immune checkpoint inhibitors have shown promise for treating upper gastrointestinal cancers, but only a small percentage of patients experience lasting benefits.
- A study analyzed data from 36 trials involving over 12,400 patients, finding that those with PD-L1-positive or EBV-positive tumors were more likely to respond to this treatment.
- The research suggests that male and Asian patients may have better survival outcomes with ICI therapy, and it emphasizes using a combination of factors to tailor immunotherapy strategies for these cancer patients.
Advanced Systemic Treatments in Patients with Moderate-to-Severe Atopic Dermatitis: Key Learnings from Physicians Practicing in Nine Asian Countries and Territories.
Dermatol Ther (Heidelb)
October 2024
Department of Dermatology, Hospital Kuala Lumpur, Kuala Lumpur and Thomson Hospital Kota Damansara, Selangor, Malaysia.
Article Synopsis
- Atopic dermatitis (AD) is a skin condition that has seen new ways of treatment recently, and how people manage it can be very different in Asia compared to other places.
- In June 2023, nine skin experts met to talk about the best ways to treat moderate-to-severe AD, focusing on the newest therapies available.
- They found that patients in Asia face challenges like how AD affects their daily life, sticking to treatment, and costs, so it’s important to use specific tests for diagnosis and monitor treatment using special scales to help manage the condition better.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!